Founders

Philippe Brudi, MD

Dr. Philippe Brudi has over 20 years of experience in the pharmaceutical industry, having held positions of increasing responsibility in clinical development and medical affairs.

Dr. Brudi was previously Executive Director of Global Medical Affairs of Diabetes & Cardiovascular Disease at Merck, where he led a global and regional medical affairs director team that wrote, implemented, and tracked the execution of global plans (including the US) developed for diabetes, atherosclerosis, thrombosis, pulmonary hypertension, and heart failure portfolios.

Other former positions Dr. Brudi has held are: Global Clinical Research & Medical Affairs Head at Novartis (Switzerland), Cardiovascular Medical Director at Bristol-Myers Squibb (France and US), and Cardiovascular Medical Advisor at Zeneca Pharma (France). With his strong communicational skills, high energy levels, and ability to solve complex problems in a fast-paced environment, Dr. Brudi holds a track record in launching new treatments for diabetes and cardiovascular disease. He is internationally connected with a diverse network of experts in metabolic diseases and cardiology.

Dr. Brudi holds an MBA from IMIS (Lyon, France) and a MD specialized in primary care from University of Nancy II (France). He is a member of the American National Lipid Association (NLA), the American Heart Association (AHA), the European Society of Cardiology (ESC), and the European Society of Atherosclerosis (EAS). He has published over 60 peer-reviewed articles and over 120 cardiovascular metabolic posters and communications.